{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=15",
    "query": {
      "condition": "High-Risk",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T21:17:43.443Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03085719",
      "title": "Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-06-30",
      "completion_date": "2027-10-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03085719"
    },
    {
      "nct_id": "NCT02186509",
      "title": "Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Diffuse Astrocytoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Pineal Gland Astrocytoma",
        "Adult Subependymal Giant Cell Astrocytoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Hyperfractionated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2015-01-30",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186509"
    },
    {
      "nct_id": "NCT02514798",
      "title": "Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Esophageal and gastric balloons",
          "type": "OTHER"
        },
        {
          "name": "Respiratory Inductance Plethysmography (RIP) system",
          "type": "OTHER"
        },
        {
          "name": "Sentec transcutaneous monitoring system",
          "type": "OTHER"
        },
        {
          "name": "High-flow humidified nasal oxygen delivery system",
          "type": "DEVICE"
        },
        {
          "name": "CPAP (Positive Control)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-07",
      "completion_date": "2018-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514798"
    },
    {
      "nct_id": "NCT05509998",
      "title": "Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "First Episode Psychosis (FEP)",
        "Clinical High Risk for Psychosis (CHR)"
      ],
      "interventions": [
        {
          "name": "Screening Method (SM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Screening and Communication Method (SCM)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 912,
      "start_date": "2023-05-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05509998"
    },
    {
      "nct_id": "NCT00345475",
      "title": "UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Birth Defects",
        "Pregnancy Complications",
        "Epilepsy",
        "Seizures"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 516,
      "start_date": "2004-12",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345475"
    },
    {
      "nct_id": "NCT05408975",
      "title": "Treating Civilian Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation (ciTBI-HDtDCS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Word Finding Difficulty",
        "Acquired Brain Injury",
        "Cognitive Change"
      ],
      "interventions": [
        {
          "name": "Active Transcranial direct current stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Sham Transcranial direct current stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 5,
      "start_date": "2023-01-01",
      "completion_date": "2024-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05408975"
    },
    {
      "nct_id": "NCT05281471",
      "title": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Platinum-refractory Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "High-grade Serous Ovarian Cancer",
        "Endometrioid Ovarian Cancer",
        "Ovarian Clear Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "olvimulogene nanivacirepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum chemotherapy: carboplatin (preferred) or cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab (or biosimilar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genelux Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 186,
      "start_date": "2022-08-31",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 33,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281471"
    },
    {
      "nct_id": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer Crombie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2023-04-06",
      "completion_date": "2029-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05800366"
    },
    {
      "nct_id": "NCT06229353",
      "title": "Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Gardasil 9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 34,
      "start_date": "2024-08-08",
      "completion_date": "2025-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06229353"
    },
    {
      "nct_id": "NCT06947395",
      "title": "Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer of the Pancreas",
        "Pancreatic Cancer",
        "Pancreas Neoplasms",
        "Pancreatic Carcinoma Stage I",
        "Pancreatic Carcinoma Stage II"
      ],
      "interventions": [
        {
          "name": "PancreaSure",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Immunovia, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2025-02-11",
      "completion_date": "2025-04-07",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-05T21:17:43.443Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • New York, New York • Pittsburgh, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06947395"
    }
  ]
}